Cargando…

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis

BACKGROUND: Disease-modifying therapies (DMTs) can reduce the risk of disability worsening in patients with relapsing forms of multiple sclerosis (RMS). High-efficacy DMTs can lead to confirmed or sustained disability improvement (CDI and SDI). OBJECTIVE AND METHODS: Post hoc analyses of data from t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cree, Bruce AC, Cohen, Jeffrey A, Reder, Anthony T, Tomic, Davorka, Silva, Diego, Piani Meier, Daniela, Laflamme, Annik K, Ritter, Shannon, Leppert, David, Kappos, Ludwig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597182/ https://www.ncbi.nlm.nih.gov/pubmed/33769117 http://dx.doi.org/10.1177/13524585211000280

Ejemplares similares

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
por: Cree, Bruce AC, et al.
Publicado: (2022)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
por: Arnold, Douglas L, et al.
Publicado: (2022)

Long-term prognostic value of longitudinal measurements of blood neurofilament levels
por: Häring, Dieter A., et al.
Publicado: (2020)

A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm
por: Tolley, Chloe, et al.
Publicado: (2020)

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
por: Kappos, Ludwig, et al.
Publicado: (2020)

Recurrent disability progression endpoints in multiple sclerosis clinical trials
por: Bühler, Alexandra, et al.
Publicado: (2022)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
por: Chalkou, Konstantina, et al.
Publicado: (2021)

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
por: Nixon, Richard, et al.
Publicado: (2014)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
por: Cohen, Jeffrey A., et al.
Publicado: (2019)

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
por: Gold, Ralf, et al.
Publicado: (2022)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
por: Cree, Bruce AC, et al.
Publicado: (2022)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
por: Migliore, S., et al.
Publicado: (2017)

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
por: Bar-Or, Amit, et al.
Publicado: (2023)

Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
por: Yeo, Tianrong, et al.
Publicado: (2021)

Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis
por: Cagol, Alessandro, et al.
Publicado: (2023)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
por: Hunter, Samuel F., et al.
Publicado: (2015)

Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
por: Hauser, Stephen L, et al.
Publicado: (2023)

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
por: Daruwalla, Cyrus, et al.
Publicado: (2023)

Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials
por: Lavery, Amy M., et al.
Publicado: (2014)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gkdqk3hrppj9rm3ojm42prm05s